New combo therapy aims to delay prostate cancer relapse in patients with limited spread

NCT ID NCT02274779

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of high-dose radiation and hormone therapy (leuprorelin) in 74 men with prostate cancer that had returned in up to 5 pelvic lymph nodes after initial treatment. The goal was to see if this approach could delay further cancer growth or relapse. Participants received radiation to the affected nodes plus six months of hormone therapy, and researchers tracked how long it took for the cancer to progress again.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Leuprorelin (Eligard) hormone therapy plus high-dose radiation therapy
What this could lead to
If successful, this combination could delay the return of prostate cancer after initial treatment, potentially extending the time before more aggressive therapy is needed.
What could go wrong
This is a small, early-phase trial (74 participants) with no control group, so results may not apply broadly. Hormone therapy has side effects like hot flashes and fatigue, and the treatment may not prevent eventual relapse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICO Paul Papin

    Angers, France

  • ICO René Gauducheau

    Saint-Herblain, 44800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.